Skip to content

Roivant Sciences ROIV Investing Cash Flow

Investing Cash Flow at other companies

Amgen logo
AmgenAMGN
-$716M-60.2%
Moderna logo
ModernaMRNA
-$76M-110%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
-$8K+96.0%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$131M+73.7%
AbbVie logo
AbbVieABBV
-$574M+21.9%
Regenxbio logo
RegenxbioRGNX
$70.59M+57.8%

Other financials

Income statement

See full
Revenue$2.5M-66.7%
Operating income-$339.2M-23.6%
Net income-$265.9M-257%
EPS (diluted)-$0.38-265%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$25.25B+226%
Enterprise value$23.93B+209%
P/S3,056.5×+2,723×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-9,183.5%-17,093pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The official record: Roivant Sciences’s 10-Q, filed August 11, 2025, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's investing cash flow?
Roivant Sciences (ROIV) reported investing cash flow of -$1.09B in Q2 2025.
How has Roivant Sciences's investing cash flow changed year-over-year?
Roivant Sciences's investing cash flow decreased by 112409.4% year-over-year, from -$965K to -$1.09B.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.